null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Atezolizumab Biosimilar (Anti-PDL1) Antibody (HDBS0009)

SKU HDBS0009
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein PD-L1
Reactivity Human
Host Species Humanized
Isotype IgG1
€431
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Atezolizumab (Anti-PDL1) Biosimilar Antibody (HDBS0009)

The Anti-PD-L1 Atezolizumab Biosimilar Monoclonal Antibody (HDBS0009) is a cutting-edge biologic designed for research in the field of immuno-oncology. This antibody, derived from rabbit cells, specifically targets the PD-L1 protein, a key immune checkpoint molecule that suppresses the body's immune response to cancer cells. The Anti-PD-L1 Atezolizumab Biosimilar Monoclonal Antibody is highly reactive with human samples, making it a valuable tool for studying the expression and function of PD-L1 in cancer cells. It is validated for use in a variety of applications, including immunohistochemistry and flow cytometry, providing researchers with versatile options for analyzing PD-L1 expression levels in different contexts.

The PD-L1 protein plays a crucial role in immune evasion by cancer cells, allowing tumors to escape detection and destruction by the immune system. By targeting PD-L1 with antibodies like Atezolizumab, researchers can potentially restore the body's natural anti-tumor immune response, leading to improved outcomes for cancer patients.Overall, the Anti-PD-L1 Atezolizumab Biosimilar Monoclonal Antibody holds great promise for advancing our understanding of cancer immunotherapy and developing more effective treatments for patients facing a variety of cancer types.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose